Loading...
Market
Story
FDA Resolves Tirzepatide Shortage; Approves Zepbound for Obstructive Sleep Apnea, Impacting $149.6B Yearly Costs
Dec 20, 2024, 09:38 PM
The U.S. Food and Drug Administration (FDA) has confirmed that the shortage of Eli Lilly's obesity drug tirzepatide, marketed as Zepbound, is resolved. This decision follows a re-evaluation of the drug's supply and means that compounding pharmacies must cease production of copycat versions within 60 to 90 days. The FDA's ruling indicates that both Mounjaro and Zepbound are no longer in short supply, which could impact the availability of cheaper alternatives. Additionally, the FDA has approved Zepbound as the first drug treatment for moderate-to-severe obstructive sleep apnea in adults with obesity, potentially expanding insurance coverage for this medication. This approval marks a significant milestone for Eli Lilly, as it addresses a common and serious condition affecting millions of adults in the U.S.
View original story
Similar markets
More than 2 million • 25%
500,000 to 1 million • 25%
1 million to 2 million • 25%
Less than 500,000 • 25%
100,000 to 200,000 • 25%
More than 300,000 • 25%
Less than 100,000 • 25%
200,000 to 300,000 • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
No • 50%
Yes • 50%
More than 30% • 25%
20% to 30% • 25%
10% to 20% • 25%
Less than 10% • 25%
Less than 60% • 25%
60% to 70% • 25%
70% to 80% • 25%
More than 80% • 25%
No • 50%
Yes • 50%
Pfizer's Danuglipron • 25%
Novo Nordisk's Wegovy • 25%
Other • 25%
AstraZeneca's Roxadustat • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%